Advertisement

Coronary Arterial Response to Injury

  • Robert S. Schwartz
  • Renu Virmani
  • Andrew Farb
Chapter

Abstract

Both stent implantation and simple balloon angioplasty induce marked injury in the coronary artery or peripheral vessels. The artery’s response to that injury is critical to the long-term success or failure of the procedures [1–3]. The coronary artery responds to injury incurred during revascularization with neointimal hyperplasia, forming neointima of varying thickness, and with thickening of the adventitia. This latter process frequently causes vessel shrinkage, or negative remodeling, and is a principal cause of restenosis when a stent is not present to resist the constriction [4–8]. When a stent is placed, neointimal hyperplasia is the determining factor for in-stent restenosis and is the major target of drug-eluting stents. Presented in this chapter are animal models and human examples of the coronary artery’s response to injury during revascularization procedures.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schwartz RS, Murphy JG, Edwards WD, et al.: Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990, 82:2190–2200.PubMedCrossRefGoogle Scholar
  2. 2.
    Schwartz RS, Murphy JG, Edwards WD, et al.: Restenosis occurs with internal elastic lamina laceration and is proportional to severity of vessel injury in a porcine coronary artery model [abstract]. Circulation 1990, 82:III-656.CrossRefGoogle Scholar
  3. 3.
    Schwartz RS, Murphy JG, Edwards WD, et al.: Coronary artery restenosis and the “virginal membrane”: smooth muscle cell proliferation and the intact internal elastic lamina. J Invasive Cardiol 1991, 3:3–8.Google Scholar
  4. 4.
    Mehran R, Mintz G, Popma J, et al.: Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol 1996, 78:618–622.PubMedCrossRefGoogle Scholar
  5. 5.
    Mintz G, Pichard A, Kent K, et al.: Endovascular stents reduce restenosis by eliminating geometric arterial remodeling: a serial intravascular ultrasound study [abstract]. J Am Coll Cardiol 1995, 95:701–705.Google Scholar
  6. 6.
    Mintz GS, Kent KM, Pichard AD, et al.: Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis. Cardiol Clin 1997, 15:17–29.PubMedCrossRefGoogle Scholar
  7. 7.
    Mintz GS, Kent KM, Pichard AD, et al.: Contribution of inadequate arterial remodeling to the development of focal coronary artery stenoses. An intravascular ultrasound study. Circulation 1997, 95:1791–1798.PubMedCrossRefGoogle Scholar
  8. 8.
    Mintz G, Kent K, Pichard A, et al.: Intravascular ultrasound insights into mechanisms of stenosis formation. Cardiol Clin 1997, 15:17–29.PubMedCrossRefGoogle Scholar
  9. 9.
    Webster MW, Chesebro JH, Fuster V: Platelet inhibitor therapy. Agents and clinical implications. Hematol Oncol Clin North Am 1990, 4:265–289.PubMedGoogle Scholar
  10. 10.
    Runge MS, Bode C: Inhibition of platelets and thrombin: implications for treatment of coronary artery thrombosis [review]. Z Kardiol 1993, 2:83–88.Google Scholar
  11. 11.
    Thornton MA, Gruentzig AR, Hollman J, et al.: Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation 1984, 69:721–727.PubMedCrossRefGoogle Scholar
  12. 12.
    Cariou R, Harousseau JL, Tobelem G: Inhibition of human endothelial cell proliferation by heparin and steroids. Cell Biol Int 1988, 12:1037–1047.Google Scholar
  13. 13.
    Pepine CJ, Hirshfeld JW, Macdonald RG, et al.: Controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation 1990, 81:1753–1761.PubMedCrossRefGoogle Scholar
  14. 14.
    Does the new angiotensin converting enzyme inhibitor Cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992, 86:100–110.Google Scholar
  15. 15.
    Ellis SG: Do ACE inhibitors or ARBs limit restenosis after stenting? Assimilating the data.J Invasive Cardiol 2001, 13:98–99.PubMedGoogle Scholar
  16. 16.
    Faxon DP: Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of Cilazapril. J Am Coll Cardiol 1995, 25:362–369.PubMedCrossRefGoogle Scholar
  17. 17.
    Gilbert SP, Weintraub WS, Talley JD, Boccuzzi SJ: Costs of coronary restenosis (Lovastatin Restenosis Trial). Am J Cardiol 1996, 77:196–199.PubMedCrossRefGoogle Scholar
  18. 18.
    Malik IS, Khan M, Beatt KJ: Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 2000, 86:810.PubMedCrossRefGoogle Scholar
  19. 19.
    Serruys PW, Foley DP, Jackson G, et al.: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999, 20:58–69.PubMedCrossRefGoogle Scholar
  20. 20.
    Corcos T, David PR, Bal PG, et al.: Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985, 109:926–931.PubMedCrossRefGoogle Scholar
  21. 21.
    O’Keefe JHJ, Giorgi LV, Hartzler GO, et al.: Effects of diltiazem on complications and restenosis after coronary angioplasty. Am J Cardiol 1991, 67:373–376.PubMedCrossRefGoogle Scholar
  22. 22.
    Unverdorben M, Kunkel B, Leucht M, Bachmann K: Reduction of restenosis after PTCA by diltiazem? Circulation 1992, 86:1–53.CrossRefGoogle Scholar
  23. 23.
    Serruys PW, Herrman JP, Simon R, et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995, 333:757–763.PubMedCrossRefGoogle Scholar
  24. 24.
    Strauss BH, van der Giessen WJ, Verdouw PD: Hirudin and restenosis. Circulation 1992, 85:1952–1953.PubMedGoogle Scholar
  25. 25.
    Emanuelsson H, Beatt KJ, Bagger JP, et al.: Long-term effects of angiopeptin treatment in coronary angioplasty. Reduction of clinical events but not angiographic restenosis. Circulation 1995, 91:1689–1696.PubMedCrossRefGoogle Scholar
  26. 26.
    Rosanio S, Tocchi M, Patterson C, Runge MS: Prevention of restenosis after percutaneous coronary interventions: the medical approach. Thromb Haemost 1999, 82 (Suppl 1):164–170.PubMedGoogle Scholar
  27. 27.
    Serruys PW: Long-term effects of angiopeptin treatment in coronary angioplasty: reduction of clinical events but not angiographic restenosis [letter; comment]. Circulation 1995, 92:2759–2760.PubMedGoogle Scholar
  28. 28.
    Serruys PW, Juilliere Y, Bertrand ME, et al.: Additional improvement of stenosis geometry in human coronary arteries by stenting after balloon dilatation. Am J Cardiol 1988, 61:71G-76G.CrossRefGoogle Scholar
  29. 29.
    Serruys PW, Strauss BH, van Beusekom HM, van der Giessen WJ: Stenting of coronary arteries: has a modern Pandora’s box been opened? J Am Coll Cardiol 1991, 17:143B–154B.CrossRefGoogle Scholar
  30. 30.
    Serruys PW, Kay IP, Disco C, et al.: Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. J Am Coll Cardiol 1999, 34:1067–1074.PubMedCrossRefGoogle Scholar
  31. 31.
    Serruys PW, Foley DP, Jackson G, et al.: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999, 20:58–69.PubMedCrossRefGoogle Scholar
  32. 32.
    Anderson HV: Restenosis after coronary angioplasty. Dis Mon 1993, 39:613–670.PubMedGoogle Scholar
  33. 33.
    Bairn DS, Levine MJ, Leon MB, et al.: Management of restenosis within the Palmaz-Schatz coronary stent (the U.S. multicenter experience). The U.S. Palmaz-Schatz Stent Investigators. Am J Cardiol 1993, 71:364–366.CrossRefGoogle Scholar
  34. 34.
    Bruining N, Sabate M, de Feyter PJ, et al.: Quantitative measurements of instent restenosis: a comparison between quantitative coronary ultrasound and quantitative coronary angiography. Catheter Cardiovasc Interv 1999, 48:133–142.PubMedCrossRefGoogle Scholar
  35. 35.
    Virmani R, Farb A, Carter AJ, Jones RM: Comparative pathology: radiation-induced coronary artery disease in man and animals. Semin Interv Cardiol 1998, 3:163–172.PubMedGoogle Scholar
  36. 36.
    Virmani R, Farb A: Pathology of in-stent restenosis. Curr Opin Lipidol 1999, 10:499–506.PubMedCrossRefGoogle Scholar
  37. 37.
    Sangiorgi G, Taylor AJ, Farb A, et al.: Histopathology of postpercutaneous transluminal coronary angioplasty remodeling in human coronary arteries. Am Heart J 1999, 138:681–687.PubMedCrossRefGoogle Scholar
  38. 38.
    Lafont A, Guzman L, Whitlow P, et al.: Restenosis after experimental angioplasty. Intimai, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995, 76:996–1002.PubMedCrossRefGoogle Scholar
  39. 39.
    Mintz G, Kent K, Satler L, et al.: Dimorphic mechanisms of restenosis after DCA and stents: a serial intravascular ultrasound study. Circulation 1995, 92:2610.Google Scholar
  40. 40.
    Waller B: “Crackers, breakers, stretchers, drillers, scrapers, shavers, burners, welders and melters”—the future treatment of atherosclerotic coronary artery disease. A clinical-morphologic assessment. J Am Coll Cardiol 1989, 13:969–987.PubMedCrossRefGoogle Scholar
  41. 41.
    Waller BF: Morphologic correlates of coronary angiographic patterns at the site of percutaneous transluminal coronary angioplasty. Clin Cardiol 1988, 11:817–822.PubMedCrossRefGoogle Scholar
  42. 42.
    Virmani R, Farb A, Carter AJ, Jones RM: Pathology of radiation-induced coronary artery disease in human and pig. Cardiovasc Radiat Med 1999, 1:98–101.PubMedCrossRefGoogle Scholar
  43. 43.
    Schwartz R, Holmes D, Jr, Topol E: The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992, 20:1284–1293.PubMedCrossRefGoogle Scholar
  44. 44.
    Farb A, Sangiorgi G, Carter AJ, et al.: Pathology of acute and chronic coronary stenting in humans. Circulation 1999, 99:44–52.PubMedCrossRefGoogle Scholar
  45. 45.
    Bayes-Genis A, Camrud AR, Jorgenson M, et al.: Pressure rinsing of coronary stents immediately before implantation reduces inflammation and neointimal hyperplasia. J Am Coll Cardiol 2001, 38:562–568.PubMedCrossRefGoogle Scholar
  46. 46.
    Ishiwata S, Verheye S, Robinson KA, et al.: Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation. J Am Coll Cardiol 2000, 35:1331–1337.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Robert S. Schwartz
  • Renu Virmani
  • Andrew Farb

There are no affiliations available

Personalised recommendations